Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Significant hair regrowth was achieved using oral finasteride 1mg, oral minoxidil 5mg daily, ketoconazole shampoo, and dermarolling. It is advised to continue this regimen for 12-18 months before considering any changes.

Dutasteride is more effective than finasteride for hair loss, with optimal dosing at 0.5mg once or twice a week to minimize side effects. Topical application may further reduce side effects while effectively lowering scalp DHT.

Finasteride may help users look younger by suppressing DHT, affecting skin and hair. Users also emphasize skincare, sunscreen, and lifestyle for maintaining a youthful appearance.

Finasteride use resulted in increased hair growth but reduced libido for some, leading users to consider topical versions to lessen side effects. Opinions varied on the trade-off between hair benefits and sexual side effects.

A user shared their 11-year experience with finasteride, noting temporary increased shedding that stopped, and advised continuing the treatment despite seasonal shedding. They reported no side effects and maintained a full head of hair.

Hair loss treatments like finasteride, minoxidil, and RU58841 are becoming more known, but many remain unaware of their effectiveness. There is hope for future advancements despite skepticism and misconceptions about current treatments.

The user experienced hair loss starting at 19 and tried treatments like finasteride and minoxidil inconsistently. They later used dutasteride, PRP, and various hair loss lotions and supplements, but faced side effects and are unsure about continuing treatment.

A user in Turkey was advised by a dermatologist to avoid finasteride due to its hormonal effects and was prescribed minoxidil, shampoo, and vitamins instead. The user is considering seeking another doctor's opinion or buying finasteride directly from a pharmacy.

A user shared their 10.5-month progress using oral finasteride, topical minoxidil, a derma roller, biotin, and Omega 3, despite losing over 150 hairs daily. They also mentioned starting "bald showers" after leg workouts for the last two months.

A user shared their 9-month progress using Propecia and minoxidil for hair loss, noting significant daily shedding. Others suggested potential vitamin/mineral deficiencies and offered encouragement.

A user shared their 4.5-month hair transformation using a homemade topical solution with 5% minoxidil and crushed finasteride pills, applied twice daily with weekly microneedling. They plan to switch to once-daily application with tretinoin gel to enhance absorption.

Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.

A 24-year-old had an FUE hair transplant in Liverpool at age 23, after starting finasteride at 20 to halt hair loss. The transplant involved 3000 grafts, and the user is satisfied with the results, noting increased confidence and no further hairline recession.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.